| Budget Amount *help |
¥18,980,000 (Direct Cost: ¥14,600,000、Indirect Cost: ¥4,380,000)
Fiscal Year 2017: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2016: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2014: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of our study was to elucidate the clinical significance of tumor suppressor CYLD down-regulation in cancer patient with poor prognosis. In this study, we revealed as follows: 1. CYLD down-regulation in tumor tissues was caused by multiple factors, such as hypoxic environment and microenvironment of the tumor. 2. Some of cell signal transduction, such as TGF-β, NF-kB, and MAPK signaling may be involved in tumor malignancy caused by CYLD down-regulation. 3. Molecular diagnosis targeted CYLD expression may be useful for predicting the effect of anticancer agents. Those results reveled the molecular function of CYLD in tumor tissues, and may open up novel strategies for establishing personalized medicine for malignant tumors.
|
